Condition: Dry Eye Syndrome (DES) · Sponsor: Pleryon Therapeutics (Hangzhou) Limited
The objective of this 2-part study is to assess the safety and tolerability of the new ocular lubricating drop ABR2 during short-term use in subjects for the temporary relief of ocular discomfort due to dryness of the eye. In Part 1, participant will receive 1 drop of ABR2 in one eye and through assessments over a 1-hour period. In Part 2, participant will use 1 drop of ABR2 at least two times a day for 28-day period (may use up to 4 times a day as needed) This is a single arm, open label study with no placebo or comparative arm.
This description comes directly from the study's public registry record.
CORE Studies · 519-888-4742 · corestudies@uwaterloo.ca
Ulli Stahl, PhD · 519-888-4742 · ustahl@uwaterloo.ca
Always discuss trial participation with your own doctor first.
| Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo | Waterloo, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07593404